Can-Fite BioPharma filed a prospectus with the US Securities and Exchange Commission for an offering of approximately 6.599 million ordinary shares. The transaction is being conducted on behalf of selling shareholders rather than the company itself.

The filing indicates that the proceeds from this secondary offering will accrue to the existing shareholders who are selling their stakes. This structure distinguishes the move from a primary capital raise intended to fund corporate operations or expansion.

Filing details

The regulatory submission was made to the SEC, marking the formal initiation of the offering process. The specific number of shares proposed for sale is fixed at roughly 6.599 million units. No additional financial metrics regarding the company's current revenue or profit margins were included in this specific filing notice.

Can-Fite BioPharma Ltd. (NYSE: CANF) reported a net loss of $4.60 million for the six months ended June 30, 2026, compared to a loss of $4.87 million in the same period last year. The biotechnology firm also announced that blinded overall survival data in its pivotal Phase III liver cancer study appears longer than anticipated.

The company generated revenues of $0.20 million, unchanged from H1 2025, derived from advance payments under existing out-licensing agreements. Research and development expenses rose 13.86% to $3.45 million, driven by acceleration in its Namodenoson and Piclidenoson programs. General and administrative expenses fell 31.40% to $1.42 million, primarily due to lower investor relations costs.

Clinical Progress

Can-Fite provided updates on three key therapeutic areas:

• Hepatocellular Carcinoma: Blinded overall survival in the ongoing pivotal Phase III study of Namodenoson appears longer than originally anticipated. The company is evaluating an earlier timing for the planned interim analysis.
• Pancreatic Cancer: A Phase 2a study of Namodenoson achieved its primary safety endpoint and demonstrated durable overall survival outcomes in heavily pretreated patients. An abstract has been accepted for presentation at the ESMO Congress 2026.
• Psoriasis: Enrolment of the first 247 patients in the pivotal Phase 3 study of Piclidenoson is complete. The study has reached the pre-specified interim analysis stage, with results expected in Q1 2027.

Financial Performance

Net financial income increased to $0.08 million from $0.02 million in the prior year, mainly due to higher interest income from bank deposits. Cash and cash equivalents stood at $7.03 million as of June 30, 2026, down from $8.53 million at year-end 2025. The decrease was primarily due to operating losses, partially offset by proceeds from share and warrant issuances.

What the Numbers Show

The narrowing of the net loss was driven entirely by operational cost control rather than revenue growth or R&D efficiency. While R&D spending accelerated by $0.42 million to support late-stage trials, G&A expenses contracted by $0.65 million. This divergence indicates that the improvement in the bottom line resulted from reduced administrative overhead, specifically investor relations costs, rather than a reduction in clinical development burn rate.